Why Nanosonics’ (ASX:NAN) Recurring Revenue Model Is Becoming Central to Its Healthcare Strategy?

Aditi Sarkar

20 August 2026 06:42 PM AEST

Why Nanosonics’ (ASX:NAN) Recurring Revenue Model Is Becoming Central to Its Healthcare Strategy?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Nanosonics (ASX:NAN) closed at AUD 3.60, down 1.10% on 20 August 2026.
The company develops infection prevention technologies used in medical device reprocessing.
H1 FY26 results highlighted Revenue of AUD 102.2 million, up 9% compared with the prior corresponding period.
Investors continue to monitor trophon installed base growth, recurring revenue, CORIS commercialisation and healthcare adoption.

Nanosonics Limited (ASX:NAN) shares closed at AUD 3.60, down 1.10% on 20 August 2026. The movement reflects a weaker Trading session as investors continue to assess the company’s infection prevention technology platform, product expansion strategy and healthcare market opportunities.

Daily share price movements can reflect changes in investor sentiment, trading activity, valuation expectations and broader market conditions. However, a single-session movement does not necessarily indicate a change in the company’s underlying fundamentals, financial position or long-term operating outlook.

Nanosonics develops medical technology solutions focused on infection prevention and improving safety during medical procedures. The company’s core platform, trophon®, is used for automated high-level disinfection of ultrasound probes, while its CORIS® system targets opportunities in endoscope reprocessing.

The broader Australian market closed higher on the day. The S&P/ASX 200 (ASX:XJO) closed at 9,083.80 points, up 0.33% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,019.90 points, up 0.37% today. Within the healthcare sector, the S&P/ASX 200 Health Care (ASX:XHJ) closed at 32,044.30 points, up 1.39% today.

Medical device technology platform

Nanosonics operates within the medical technology sector, focusing on infection prevention solutions used in healthcare environments.

The company’s Business model combines Capital equipment sales with Recurring Revenue generated through consumables and service activities. This recurring component is linked to the installed base of devices operating across healthcare facilities.

Investors generally assess medical device companies through factors including installed base growth, recurring revenue expansion, regulatory approvals, commercial adoption, product development and healthcare customer relationships.

The trophon platform remains central to Nanosonics’ operations, with the company continuing to expand its installed base and upgrade existing systems. The company is also developing CORIS, a technology platform designed to address endoscope reprocessing.

The healthcare technology sector is influenced by regulatory requirements, hospital Investment cycles, healthcare spending and the adoption of new clinical technologies.

Financial performance and product expansion

Nanosonics’ FY26 half-year results highlighted continued growth across its medical device platform. The company reported total revenue of AUD 102.2 million for the six months ended 31 December 2025, up 9% compared with the prior corresponding period. Recurring revenue increased 9% to AUD 75.7 million, while capital revenue increased 9% to AUD 26.5 million.

The company reported Operating Margin of AUD 8.5 million, up 27% compared with the prior corresponding period. Earnings before interest and tax (EBIT) was AUD 8.4 million, while operating profit before tax was AUD 10.6 million.

Operationally, Nanosonics installed 2,070 new trophon units during H1 FY26, increasing its cumulative installed base by 1,080 units to 38,080 devices. The company also recorded 980 upgrade sales in North America, up 61% compared with the prior corresponding period.

North America remained an important market, generating revenue of AUD 93.2 million during the period, including AUD 67.7 million in recurring revenue and AUD 25.5 million in capital revenue.

Nanosonics also progressed CORIS commercialisation activities, achieving regulatory milestones and commencing controlled market release. The company indicated that CORIS development and commercialisation remained a key growth initiative beyond FY26.

The company reported a strong cash position, with cash and cash equivalents of AUD 159.8 million at the end of H1 FY26, supporting product development, commercialisation activities and capital management initiatives.

Factors investors generally monitor

Nanosonics’ performance is influenced by healthcare technology adoption, regulatory progress, hospital demand, installed base expansion and recurring revenue growth.

The installed base of medical devices is an important metric because it supports future consumables and service revenue. Investors generally monitor new device placements, upgrades and utilisation levels across healthcare facilities.

Recurring revenue growth is another key consideration. Consumables and service income can provide more predictable revenue streams compared with equipment sales, making customer retention and device usage important factors.

Regulatory approvals and commercialisation milestones remain critical for new products. CORIS represents an additional opportunity within endoscope reprocessing, but investors continue to monitor development timelines and market adoption.

Healthcare capital spending cycles also influence demand. Hospitals and healthcare providers typically assess equipment purchases based on budgets, clinical requirements and operational priorities.

Competition within medical technology is another factor. Companies need to maintain product differentiation, clinical value and customer relationships to support adoption.

Understanding the share price movement

Nanosonics’ 1.10% share price decline on 20 August 2026 may reflect short-term changes in investor sentiment, trading activity or positioning within the healthcare sector. However, daily share price movements alone do not necessarily represent changes in the company’s underlying fundamentals.

Healthcare technology stocks can experience short-term Volatility as investors reassess product adoption, regulatory milestones and future growth expectations.

For Nanosonics, investors are likely to continue monitoring trophon performance, recurring revenue growth, CORIS commercialisation and global healthcare adoption.

Conclusion

Nanosonics (ASX:NAN) closed at AUD 3.60, down 1.10% on 20 August 2026. The company continues to focus on infection prevention technologies through its trophon platform while progressing CORIS commercialisation.

While the daily share price movement reflects market activity, investors generally assess Nanosonics through broader factors including installed base expansion, recurring revenue growth, regulatory progress, product development and healthcare adoption. H1 FY26 results highlighted revenue growth, higher recurring revenue and continued advancement of the company’s medical technology pipeline.

FAQs

Q: What was Nanosonics’ share price movement on 20 August 2026?

A: Nanosonics (ASX:NAN) closed at AUD 3.60, down 1.10% on 20 August 2026.

Q: What does Nanosonics do?

A: Nanosonics develops infection prevention technologies used in medical device reprocessing, including the trophon ultrasound probe disinfection platform.

Q: What were Nanosonics’ key H1 FY26 results?

A: Nanosonics reported revenue of AUD 102.2 million, recurring revenue of AUD 75.7 million and operating margin of AUD 8.5 million in H1 FY26.

Q: What is CORIS?

A: CORIS is Nanosonics’ endoscope reprocessing technology platform being progressed through commercialisation activities.

Q: What factors influence Nanosonics’ performance?

A: Investors generally monitor installed base growth, recurring revenue, regulatory progress, product adoption, healthcare spending and commercialisation milestones.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.